Drug Type Small molecule drug |
Synonyms Janacti, Pioglitazine/sitagliptin, Sitagliptin/pioglitazone + [2] |
Target |
Action inhibitors, agonists |
Mechanism DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors), PPARγ agonists(Peroxisome proliferator-activated receptor γ agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedNDA/BLA |
First Approval Date- |
Regulation- |
Molecular FormulaC19H21ClN2O3S |
InChIKeyGHUUBYQTCDQWRA-UHFFFAOYSA-N |
CAS Registry112529-15-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 2 | NDA/BLA | European Union | - |
Not Applicable | - | 20 | fyjxqidpru(wslnvhcgyv) = gimdhqnmtr ckyisuzjqx (nescybhfvd ) View more | - | 01 Jun 2021 | ||
Placebo | fyjxqidpru(wslnvhcgyv) = ydyqnbwenh ckyisuzjqx (nescybhfvd ) View more |